In the PROTECT AF ( Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation ) trial that evaluated patients with nonvalvular atrial fibrillation ( NVAF ) , left atrial appendage ( LAA ) occlusion was noninferior to warfarin for stroke prevention , but a periprocedural safety hazard was identified .